A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity

Biomedical Materials

Volumn 5, Issue 6, 2010, Pages

  Liu, Jie ^a   Qiu, Zhiye ^a   Wang, Shenqi ^a   Zhou, Lei ^a   Zhang, Shengmin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EMULSIFICATION; ENCAPSULATION; HYDROPHILICITY; LACTIC ACID; ORGANIC POLYMERS; ORGANIC SOLVENTS; POLYMERS; SURFACE ACTIVE AGENTS;

ANTI-TUMOR ACTIVITIES; AQUEOUS PHASE; CANCER CELLS; CELLULAR UPTAKE; CHEMOTHERAPEUTIC DRUGS; DAUNORUBICIN; EMULSION METHOD; EMULSION SOLVENTS; ENCAPSULATION EFFICIENCY; GLYCOLIC ACIDS; HIGH LOADINGS; HL-60 CELLS; HYDROPHILIC DRUGS; IN-VITRO; NANOPARTICLE FORMULATION; PARTICLE FORMATIONS; PLGA NANOPARTICLES; POLY(D ,L-LACTIC ACID); POLYMERIC NANOPARTICLES; PREPARATION PARAMETERS; SPECIFIC SITES; SUSTAINED RELEASE;

NANOPARTICLES;

DAUNORUBICIN; NANOPARTICLE; ORGANIC SOLVENT; POLYGLACTIN; POLYLACTIC ACID; POLYMER; SURFACTANT; ANTINEOPLASTIC AGENT; LACTIC ACID; NANOCAPSULE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ABSORPTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DIFFUSION; DOUBLE EMULSION SOLVENT EVAPORATION DIFFUSION METHOD; DRUG CYTOTOXICITY; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; EVAPORATION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PARAMETER; PARTICLE SIZE; SOLVENT EXTRACTION; SUSTAINED DRUG RELEASE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; DRUG FORMULATION; METHODOLOGY; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DAUNORUBICIN; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG COMPOUNDING; EMULSIONS; HL-60 CELLS; HUMANS; LACTIC ACID; NANOCAPSULES; POLYGLYCOLIC ACID;

EID: 78650771101     PISSN: 17486041     EISSN: 1748605X     Source Type: Journal    
DOI: 10.1088/1748-6041/5/6/065002     Document Type: Article

References (47)

1. Redaelli A, Botteman M F, Stephens J M, Brandt S and Pashos C L 2004 Economic burden of acute myeloid leukemia: a literature review Cancer Treat. Rev. 30 237-47 (Pubitemid 38477269)
2. Lowenberg B, Downing J R and Burnett A 1999 Acute myeloid leukemia New Engl. J. Med. 341 1051
3. Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I, Head D R, Appelbaum F R and Willman C L 1997 Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood 89 3323-9
4. Gewirtz D A 1999 A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem. Pharmacol. 57 727-41
5. Smith R E, Bryant J, DeCillis A and Anderson S 2003 Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience J. Clin. Oncol. 21 1195
6. Ghosh A K, Khan S, Marini F, Nelson J A and Farquhar D 2000 A daunorubicin [beta]-galactoside prodrug for use in conjunction with gene directed enzyme prodrug therapy Tetrahedron Lett. 41 4871-4 (Pubitemid 30431119)
7. Ax W, Soldan M, Koch L and Maser E 2000 Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction Biochem. Pharmacol. 59 293-300 (Pubitemid 30001756)
8. Fan L, Li F, Zhang H, Wang Y, Cheng C, Li X, Gu C, Yang Q, Wu H and Zhang S 2010 Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance Biomaterials 31 5634-42
9. Hans M L and Lowman A M 2002 Biodegradable nanoparticles for drug delivery and targeting Curr. Opin. Solid State Mater. Sci. 6 319-27
10. Cleland J L, Johnson O F L, Putney S and Jones A J S 1997 Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development Adv. Drug Deliv. Rev. 28 71-84 (Pubitemid 27497674)
11. Anderson J M and Shive M S 1997 Biodegradation and biocompatibility of PLA and PLGA microspheres Adv. Drug Deliv. Rev. 28 5-24
12. Maeda H, Bharate G Y and Daruwalla J 2009 Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 409-19
13. Hino T, Kawashima Y and Shimabayashi S 2000 Basic study for stabilization of w/o/w emulsion and its application to transcatheter arterial embolization therapy Adv. Drug Deliv. Rev. 45 27-45
14. Fahmy T M, Fong P M, Goyal A and Saltzman W M 2005 Targeted for drug delivery Mater. Today 8 18-26 (Pubitemid 41023877)
15. Lin R and Ng S 2005 In vitro study of anticancer drug doxorubicin in PLGA-based microparticles Biomaterials 26 4476-85
16. Dong Y and Feng S S 2004 Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs Biomaterials 25 2843-9
17. Brigger I, Dubernet C and Couvreur P 2002 Nanoparticles in cancer therapy and diagnosis Adv. Drug Deliv. Rev. 54 631-51
18. Roovers D J, van Vliet M, Bloem A C and Lokhorst H M 1999 Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines Leuk. Res. 23 539-48
19. Sahana D K, Mittal G, Bhardwaj V and Kumar M 2007 PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug J. Pharm. Sci. 97 1530-42
20. Barichello J M, Morishita M, Takayama K and Nagai T 1999 Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method Drug Dev. Ind. Pharm. 25 471-6
21. Anand P, Nair H B, Sung B, Kunnumakkara A B, Yadav V R, Tekmal R R and Aggarwal B B 2010 Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo Biochem. Pharmacol. 79 330-8
22. Rosca I D, Watari F and Uo M 2004 Microparticle formation and its mechanism in single and double emulsion solvent evaporation J. Control. Release 99 271-80
23. Zambaux M F, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso M J, Labrude P and Vigneron C 1998 Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method J. Control. Release 50 31-40 (Pubitemid 28044098)
24. Murakami H, Kobayashi M, Takeuchi H and Kawashima Y 1999 Preparation of poly(lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method Int. J. Pharm. 187 143-52 (Pubitemid 29443894)
25. Govender T, Stolnik S, Garnett M C, Illum L and Davis S S 1999 PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug J. Control. Release 57 171-85 (Pubitemid 29062869)
26. Tewes F, Munnier E, Antoon B, Ngaboni Okassa L, Cohen-Jonathan S, Marchais H, Douziech-Eyrolles L, Souce M, Dubois P and Chourpa I 2007 Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods Eur. J. Pharm. Biopharm. 66 488-92
27. Cohen-Sela E, Teitlboim S, Chorny M, Koroukhov N, Danenberg H D, Gao J and Golomb G 2009 Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity J. Pharm. Sci. 98 1452-62
28. Andrivon W, Monneret C, Nafziger J, Florent J C and Guillosson J J 1998 A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance Leuk. Res. 22 719-25
29. He Q and Jiang D 1999 A novel aminosteroid is active for proliferation inhibition and differentiation induction of human acute myeloid leukemia HL-60 cells Leuk. Res. 23 369-72
30. Pae H O, Seo W G, Kim N Y, Oh G S, Kim G E, Kim Y H, Kwak H J, Yun Y G, Jun C D and Chung H T 2001 Induction of granulocytic differentiation in acute promyelocytic leukemia cells (HL-60) by water-soluble chitosan oligomer Leuk. Res. 25 339-46
31. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg H D and Golomb G 2009 A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles J. Control. Release 133 90-5
32. Mora-Huertas C E, Fessi H and Elaissari A 2010 Polymer-based nanocapsules for drug delivery Int. J. Pharm. 385 113-42
33. Takenaga M, Yamaguchi Y, Kitagawa A, Ogawa Y, Kawai S, Mizushima Y and Igarashi R 2004 Optimum formulation for sustained-release insulin Int. J. Pharm. 271 85-94
34. Yang Y Y, Chung T S, Bai X L and Chan W K 2000 Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method Chem. Eng. Sci. 55 2223-36
35. Kuntsche J, Koch M H J, Steiniger F and Bunjes H 2010 Influence of stabilizer systems on the properties and phase behavior of supercooled smectic nanoparticles J. Colloid Interface Sci. 350 229-39
36. Dubernet C 1995 Thermoanalysis of microspheres Thermochim. Acta 248 259-69
37. Mu L and Feng S S 2002 Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol) J. Control. Release 80 129-44
38. Bouissou C, Rouse J J, Price R and Van Der Walle C F 2006 The influence of surfactant on PLGA microsphere glass transition and water sorption: remodeling the surface morphology to attenuate the burst release Pharm. Res. 23 1295-305 (Pubitemid 43946151)
39. O'Hagan D T, Jeffery H and Davis S S 1994 The preparation and characterization of poly(lactide-co-glycolide) microparticles: III. Microparticle/polymer degradation rates and the in vitro release of a model protein Int. J. Pharm. 103 37-45
40. Cui F, Cun D, Tao A, Yang M, Shi K, Zhao M and Guan Y 2005 Preparation and characterization of melittin-loaded poly(DL-lactic acid) or poly(DL-lactic-co-glycolic acid) microspheres made by the double emulsion method J. Control. Release 107 310-9
41. Cartiera M S, Johnson K M, Rajendran V, Caplan M J and Saltzman W M 2009 The uptake and intracellular fate of PLGA nanoparticles in epithelial cells Biomaterials 30 2790-8
42. Yoo H S, Lee K H, Oh J E and Park T G 2000 In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates J. Control. Release 68 419-31
43. Liu J, Jiang Z, Zhang S and Saltzman W M 2009 Poly([omega]- pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery Biomaterials 30 5707-19
44. Lotfi K, Zackrisson A L and Peterson C 2002 Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance Cancer Lett. 178 141-9
45. Miglietta A, Cavalli R, Bocca C, Gabriel L and Rosa Gasco M 2000 Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel Int. J. Pharm. 210 61-7
46. Talelli M, Iman M, Varkouhi A K, Rijcken C J F, Schiffelers R M, Etrych T, Ulbrich K, van Nostrum C F, Lammers T and Storm G 2010 Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin Biomaterials 31 7797-804
47. Ma P, Dong X, Swadley C L, Gupte A, Leggas M, Ledebur H C and Mumper R J 2009 Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia J. Biomed. Nanotechnol. 5 151-61